Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment
Authors
Keywords
-
Journal
LIVER INTERNATIONAL
Volume 35, Issue 8, Pages 2001-2008
Publisher
Wiley
Online
2015-01-05
DOI
10.1111/liv.12778
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
- (2014) Mario Scartozzi et al. INTERNATIONAL JOURNAL OF CANCER
- In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
- (2014) Ramona Rudalska et al. NATURE MEDICINE
- Human and Mouse VEGFA-Amplified Hepatocellular Carcinomas Are Highly Sensitive to Sorafenib Treatment
- (2014) E. Horwitz et al. Cancer Discovery
- Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib
- (2013) D. Chen et al. EJSO
- Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma
- (2013) Nicola Personeni et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
- (2013) Ann-Lii Cheng et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase II Randomized Dose Escalation Trial of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
- (2013) L. Rimassa et al. ONCOLOGIST
- Molecular mechanisms of sorafenib action in liver cancer cells
- (2012) Melchiorre Cervello et al. CELL CYCLE
- Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
- (2012) J. M. Llovet et al. CLINICAL CANCER RESEARCH
- Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib
- (2012) A. Lachenmayer et al. CLINICAL CANCER RESEARCH
- The relation of vascular endothelial growth factor (VEGF) gene polymorphisms on VEGF levels and the risk of vasoocclusive crisis in sickle cell disease
- (2012) Hebah H. Al-Habboubi et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Everolimus Augments the Effects of Sorafenib in a Syngeneic Orthotopic Model of Hepatocellular Carcinoma
- (2011) A.-C. Piguet et al. MOLECULAR CANCER THERAPEUTICS
- Glutamine Synthetase Immunostaining Correlates with Pathologic Features of Hepatocellular Carcinoma and Better Survival after Radiofrequency Thermal Ablation
- (2010) B. Dal Bello et al. CLINICAL CANCER RESEARCH
- The role of signaling pathways in the development and treatment of hepatocellular carcinoma
- (2010) S Whittaker et al. ONCOGENE
- Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements
- (2010) Yujin Hoshida et al. SEMINARS IN LIVER DISEASE
- Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitrostudy
- (2009) Zhe Zhang et al. BMC Medicine
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
- (2008) D. Y. Chiang et al. CANCER RESEARCH
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection
- (2007) Klaus Juergen Schmitz et al. JOURNAL OF HEPATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started